Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612434 | 0.91 | AVPR1A (0.52) | AVPR1ACNR1DRD4ALDH1A1RBP4 | |
| Hydrochloric Acid SCHEMBL612591 | 0.90 | AVPR1A (0.51) | AVPR1ACNR1DRD4ALDH1A1RBP4 | |
| SCHEMBL615132 | 0.89 | CNR1 (0.47) | AVPR1ACNR1ALDH1A1RBP4MGLL | |
| SCHEMBL613526 | 0.89 | CNR1 (0.47) | AVPR1ACNR1ALDH1A1RBP4MGLL | |
| SCHEMBL613475 | 0.89 | AVPR1A (0.51) | AVPR1ACNR1ALDH1A1RBP4OPRL1 | |
| SCHEMBL614775 | 0.89 | RBP4 (0.53) | AVPR1ACNR1RBP4 | |
| SCHEMBL613555 | 0.88 | AVPR1A (0.62) | AVPR1ACNR1DRD4ALDH1A1OPRL1 | |
| Hydrochloric Acid SCHEMBL614893 | 0.88 | AVPR1A (0.51) | AVPR1ACNR1ALDH1A1RBP4TPSAB1 | |
| SCHEMBL613528 | 0.88 | MEN1 (0.55) | AVPR1ACNR1DRD4ALDH1A1RBP4 | |
| SCHEMBL615864 | 0.88 | AVPR1A (0.59) | AVPR1ACNR1RBP4MGLLTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102295636-A | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | — | 2011-12-28 | — | — | CN | claimed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | claimed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | claimed |
| JP-2009502859-A | — | — | 2009-01-29 | — | — | JP | claimed |
| CN-101277945-A | Indol-3-yl-carbonyl-piperidine and piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | claimed |
| EP-1917255-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | claimed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| CN-102295636-A | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| CN-101277945-A | Indol-3-yl-carbonyl-piperidine and piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | disclosed |
| EP-1917255-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885CNR1 31/4885DRD4 206/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885CNR1 31/4885DRD4 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.